Qiagen is a diagnostics and research company with a strong Piotroski financial health score of 8 out of 9 and consistent earnings delivery, but thin 3% upside to analyst targets, a confirmed price downtrend, and an unfavorable reward-to-risk ratio of 0.58 suggest the current entry point offers insufficient margin of safety.
Thesis pillars
- Thin Upside Poor Asymmetry↑Improving
- Strong Financial Health Score→Stable
- Consistent Earnings Delivery↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Qiagen N.V. (QGEN) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $50.83 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative news sentiment (-0.67).
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing... Read more
Sell if holding. Analyst target reached at $50.83 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative news sentiment (-0.67). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 28, 2026Recent Developments — Qiagen N.V.
Latest news
- NEWS QGEN Downgraded by Barclays -- Price Target Lowered to $53 - GuruFocus — GuruFocus Oct 28, 2026 negative
- NEWS Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Qiagen (NYSE:QGEN) Rating Lowered to "Neutral" at JPMorgan Chase & Co. - MarketBeat — MarketBeat Oct 28, 2026 negative
- NEWS Qiagen's Rally Raises The Bar As Back-Half Recovery Faces Its First Real Test - Finviz — Finviz Oct 28, 2026 neutral
- NEWS Citigroup Forecasts Strong Price Appreciation for Qiagen (NYSE:QGEN) Stock - MarketBeat — MarketBeat Oct 27, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-05T11:49:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $50.83 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative news sentiment (-0.67). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $49.03. Score 5.1/10, moderate confidence.
Analyst target $42.65 reached (−16.1% from $50.83); no take-profit level is published. Prior stop was $49.03. Stop-loss: $49.03.
Analyst target reached - limited upside remaining; Negative news sentiment (-0.67); Earnings estimates trending DOWN.
Qiagen N.V. trades at a P/E of 26.1 (forward 19.5). TrendMatrix value score: 5.0/10. Verdict: Sell.
21 analysts rate QGEN, with a consensus score of 3.5/5. 11 analysts publish price targets averaging $49.
What does Qiagen N.V. do?Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide....
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.